Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innocan Pharma Corp (OP: INNPF )

0.1900 UNCHANGED
Streaming Delayed Price Updated: 3:20 PM EDT, Aug 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1900
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1900
Today's Range 0.1900 - 0.1900
52wk Range 0.1820 - 0.3545
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. 
Via Benzinga
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-21.84%
-21.84%
1 Month
N/A
N/A
3 Month
-9.13%
-9.13%
6 Month
-15.89%
-15.89%
1 Year
-0.05%
-0.05%

More News

Read More
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
Via Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
Via Benzinga
Exposures Product Safety
4 CBD Stocks in the Canadian Capital Market
Via Benzinga
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
Via Benzinga
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Via Benzinga
Cannabis Stock Gainers And Losers From August 25, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma Secures $1.4M Via Private Placement
Via Benzinga
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma To Secure Up To $3M Via Private Placement Of Units At A 9% Prime Above Share Price
Via Benzinga
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For July 21, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From August 14, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma Q1 Revenue Grows 500%, Here Is What You Need To Know
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Innocan Pharma FY22 Revenue Grows 1205% To $2.6M, Here Is What You Need To Know
Via Benzinga
Can Liposomal CBD Injection Help Dogs With Polyarthritis? Innocan Pharma Reports Clinical Success
Via Benzinga
Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know
Via Benzinga
Innocan Pharma Provides an Operational Update
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
Via Newsfile
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Via Newsfile
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.